Security Snapshot

MIRUM PHARMACEUTICALS INC - NOTE 4.000% 5/0 Institutional Ownership

CUSIP: 604749AB7

13F Institutional Holders and Ownership History from Q2 2024 to Q1 2026

Latest Period

Q1 2026

Institutions Reporting

34

Principal

$291,835,670

Price (% of par)

298.2%

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 3 signals
Principal change
-$4,835,000
Market value change
-$3,377,707
Number of holders
34
Issuer context 1 identity field
SEC-reported market price (% of par)
298.2%
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • 604749AB7 - MIRUM PHARMACEUTICALS INC - NOTE 4.000% 5/0 is tracked under CUSIP 604749AB7.
  • 34 institutions reported positions in Q1 2026.
  • Schedule 13D/13G significant owner rows are not currently available.

Change

  • Holder count moved from 43 to 34 between Q4 2025 and Q1 2026.
  • SEC-reported value moved from $784,694,693 to $873,221,649.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 34 institutions filings for Q1 2026.

Open SEC Evidence

Security key

604749AB7

Latest holder period

Q1 2026

13F holders

34

13D/G owners

0

CIK / CUSIP context first

As of 31 Mar 2026, 34 institutional investors reported holding $291,835,670 in principal (par value) of MIRUM PHARMACEUTICALS INC - NOTE 4.000% 5/0.

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
8
Latest
Q1 2026
Rows shown
1-8 of 8
Period Principal Value Change Price (% of par) (Median) Investors
2026 Q1 $291,835,670 $873,221,649 -$3,377,707 298.2% 34
2025 Q4 $303,583,670 $784,694,693 -$60,590,670 258.15% 43
2025 Q3 $307,636,670 $740,546,108 +$45,284,221 240.15% 41
2025 Q2 $300,281,225 $533,109,908 -$1,145,567 177.38% 41
2025 Q1 $300,918,225 $490,695,428 +$8,812,607 162.6% 38
2024 Q4 $296,243,895 $450,609,974 -$6,400,893 152.25% 35
2024 Q3 $296,659,945 $437,996,520 -$2,614,830 146.89% 36
2024 Q2 $297,525,608 $401,072,370 +$398,393,673 133.99% 30
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .